Just - Evotec Biologics selected by U.S. Department of Defense for
Manufacturing Optimization Program

EQS-News: Evotec SE / Key word(s): Miscellaneous
Just - Evotec Biologics selected by U.S. Department of Defense for
Manufacturing Optimization Program

25.06.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

__TOKEN__0__0__

     * Just - Evotec Biologics will deliver an ultra-rapid,
     cost-efficient biotherapeutics manufacturing platform solution for
     the DOD's Manufacturing Optimization Program

     * Manufacturing solution includes seamless integration of
     accelerated mAb drug development into the overall Manufacturing
     Optimization Program

     * Manufacturing Optimization Program effort enhances U.S.
     Government's rapid response capabilities for biologics MCMs in
     response to emergency situations

Hamburg, Germany, 25 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) today announced that its Seattle-based subsidiary, Just -
Evotec Biologics, Inc., was selected by the U.S. Department of Defense
("DOD") to develop an accelerated monoclonal antibody ("mAb") development
and manufacturing solution for the DOD's Manufacturing Optimization Program.
The multi-year program award, valued up to $ 39 m, will support the U.S.
Government's effort to enhance its rapid response capabilities for biologics
medical countermeasures ("MCMs").

Under the program, Just - Evotec Biologics will focus its expertise on
project activities and technologies that will significantly decrease the
time for development, manufacturing, and CMC-focused regulatory efforts.
These innovations will significantly increase the speed to first clinical
doses while maintaining high mAb quality, productivity, and safety criteria.
Activities include developing and testing process development optimization,
improving efficiencies in cGMP manufacturing and drug product release, and
enhancing operational and resource workflows. The program will culminate in
testing the optimized system components through rapid response exercises,
starting with a DOD-identified MCM antibody sequence, and ending with the
manufacturing of clinical doses.

The Just - Evotec Biologics' optimized manufacturing solution will
seamlessly integrate into the U.S. Government's rapid emergency response
system spanning the entire drug development lifecycle, with an overall
100-calendar day target timeline for advancing drug development from
pathogen identification through fielding of doses.

Dr Linda Zuckerman, Executive Vice President Global Head Biotherapeutics at
Just - Evotec Biologics stated: "We are proud to be selected to provide our
expertise and technologies in support of this important program. We are
excited to push our current end-to-end biologics development platform and
partner with the DOD to bring 'next level' development of fast, high
quality, cost efficient mAbs to the clinic."

Dr Matthias Evers, Chief Business Officer of Evotec, commented: "It is an
honor to further support and expand our work for the DOD with this program
of strategic importance that could bring further innovation in mAb
development and manufacturing to the industry. We strongly believe that by
focusing on the design and application of innovative technologies we will
dramatically expand global access to biotherapeutics."

Mr. Bruce Goodwin, Joint Project Lead at JPEO-CBRND (JPL for CBRND Enabling
Biotechnologies): "The Joint Program Executive Office for Chemical,
Biological, Radiological and Nuclear Defense (JPEO-CBRND) is thrilled to
reinforce its collaboration with Just - Evotec Biologics in the context of
an innovative program. This strategic alliance enables us to harness the
power of advancements in manufacturing as part of our readiness and agile
reaction approach, ensuring that we are prepared to swiftly develop medical
countermeasures in response to a diverse array of biologic threats."

The contract was awarded to Just - Evotec Biologics by the DOD's Joint
Program Executive Office for Chemical, Biological, Radiological, and Nuclear
Defense (JPEO-CBRND), Joint Product Lead for Enabling Biotechnologies (JPL
CBRND EB) under contract number MCDC2301-001.

Prior contracts awarded to Just - Evotec Biologics by the DOD include the
COVID project, which enabled the manufacture of doses under tight timelines
and restricted resourcing, and Accelerated Antibodies, which focuses on mAb
prophylactic therapies for Plague and Orthopoxviruses.

About the Manufacturing Optimization Program
The Joint Program Executive Office for Chemical, Biological, Radiological,
and Nuclear Defense requires innovative approaches that can accelerate the
drug development lifecycle through production and delivery. Under this
prototype project, the United States Government ("USG") is seeking optimized
manufacturing platforms and techniques that can be seamlessly incorporated
into an integrated emergency response system that covers the entire drug
development lifecycle. Innovative manufacturing solutions will support an
overall 100-calendar-day target timeline for advancing drug development from
pathogen identification through fielding of doses. This is necessary, due to
a dynamically changing chemical/bioweapons threat landscape and increasing
potential that the war fighter may encounter unanticipated threats in the
field. Further, drug development timelines are historically lengthy,
limiting response capabilities in an emergency scenario. The primary
objective of this effort is to identify, develop and demonstrate optimized
manufacturing platforms/techniques that can enhance the USG's rapid response
capabilities for biologics MCMs.

About Just - Evotec Biologics
Just - Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry
biologics platform company that leverages AI/ML technologies and
world-leading molecular design, cell line development, process
intensification and continuous manufacturing strategies to advance
biotherapeutics from discovery through clinical stages to commercial launch.
The Just - Evotec Biologics team combines deep industry experience in the
fields of data, protein, process, and manufacturing sciences including
automation with highly integrated and flexible capabilities to break through
the scientific and economic barriers associated with the development of
protein therapeutics. Our focus is to accelerate and expand access to
biotherapeutics through scientific and technological innovation for our
proprietary projects and on behalf of our partners. Learn more at
www.just-evotecbiologics.com.

About Evotec SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec provides high value pipeline
co-creating partnerships and solutions to all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare
stakeholders. Evotec has strategic activities in a broad range of currently
underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for innovative
therapeutics and has to-date established a portfolio of more than 200
proprietary and co-owned R&D projects from early discovery to clinical
development. Evotec operates globally with more than 5,000 highly qualified
people. The Company's sites in Europe and the USA offer highly synergistic
technologies and services and operate as complementary clusters of
excellence. For additional information please go to www.evotec.com and
follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

For further information, please contact:

Media

Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com

Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com


---------------------------------------------------------------------------

25.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1931047

End of News EQS News Service
---------------------------------------------------------------------------

1931047 25.06.2024 CET/CEST